A comparative study of genotoxic effects in the treatment of trichomonas vaginalis infection: metronidazole or nalidixic acid

We performed a prospective randomized study to compare the potential genotoxic effects of metronidazole and nalidixic acid which they are used in the treatment of Trichomonas vaginalis infection. 20 patients with Trichomonas vaginalis infections participated in this study. 14 patients with vaginal t...

Full description

Saved in:
Bibliographic Details
Published in:Archives of gynecology and obstetrics 2000-07, Vol.264 (1), p.20-23
Main Authors: Akyol, D, Mungan, T, Baltaci, V
Format: Article
Language:English
Subjects:
Acids
Adult
Animals
Antitrichomonal Agents - therapeutic use
Condoms
Female
Gene Frequency
Genes - drug effects
Humans
Infections
Metronidazole - therapeutic use
Middle Aged
Mutagenicity Tests
Nalidixic Acid - therapeutic use
Parasitic diseases
Prospective Studies
Sexually transmitted diseases
Sister Chromatid Exchange
STD
Trichomonas vaginalis - genetics
Trichomonas Vaginitis - drug therapy
Trichomonas Vaginitis - parasitology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c311t-6f68922ce00570105108d99e299b2acadf08c26d42e39793207396cb331fbe253
cites
container_end_page 23
container_issue 1
container_start_page 20
container_title Archives of gynecology and obstetrics
container_volume 264
creator Akyol, D
Mungan, T
Baltaci, V
description We performed a prospective randomized study to compare the potential genotoxic effects of metronidazole and nalidixic acid which they are used in the treatment of Trichomonas vaginalis infection. 20 patients with Trichomonas vaginalis infections participated in this study. 14 patients with vaginal trichomoniasis were treated with therapeutic doses of metronidazole 250 mg 3 times/d and six patients were treated with nalidixic acid 400 mg twice a day for 10 d. The genotoxic potential of a variety of mutagenic and carcinogenic agents can be evaluated by sister-chromatid exchange (SCE) test as a rapid cytogenetic test. An increased number of exchanges in lymphocytes reflects the influence of mutagens. No significant difference was observed in the SCE frequency of metronidazole treated patient however, a statistically significant increase (P
doi_str_mv 10.1007/PL00007476
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2261890375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2261890375</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-6f68922ce00570105108d99e299b2acadf08c26d42e39793207396cb331fbe253</originalsourceid><addsrcrecordid>eNpNkE1LAzEQhoMotlYv_gAJeBOqk6SbbLyV4hcU9KDnJZudbVO6m5qkxQr-d7u0oHOZOTzzMvMQcsnglgGou7cp7EqNlDwifTYSfAiKsWPSB93NIFWPnMW4AGA8z-Up6THQeSaZ6JOfMbW-WZlgktsgjWldbamv6Qxbn_yXsxTrGm2K1LU0zZGmgCY12KaOSsHZuW98ayLdmJlrzdJ1ZLfhfHtPG0zBt64y336J1AfaEZXrco111Tk5qc0y4sWhD8jH48P75Hk4fX16mYynQysYS0NZy1xzbhEgU8AgY5BXWiPXuuTGmqqG3HJZjTgKrXZPgxJa2lIIVpfIMzEg1_vcVfCfa4ypWPh12N0SC84lyzUI1VE3e8oGH2PAulgF15iwLRgUneniz_QOvjpErssGq3_oXq34BV_YeU8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2261890375</pqid></control><display><type>article</type><title>A comparative study of genotoxic effects in the treatment of trichomonas vaginalis infection: metronidazole or nalidixic acid</title><source>Springer Link</source><creator>Akyol, D ; Mungan, T ; Baltaci, V</creator><creatorcontrib>Akyol, D ; Mungan, T ; Baltaci, V</creatorcontrib><description>We performed a prospective randomized study to compare the potential genotoxic effects of metronidazole and nalidixic acid which they are used in the treatment of Trichomonas vaginalis infection. 20 patients with Trichomonas vaginalis infections participated in this study. 14 patients with vaginal trichomoniasis were treated with therapeutic doses of metronidazole 250 mg 3 times/d and six patients were treated with nalidixic acid 400 mg twice a day for 10 d. The genotoxic potential of a variety of mutagenic and carcinogenic agents can be evaluated by sister-chromatid exchange (SCE) test as a rapid cytogenetic test. An increased number of exchanges in lymphocytes reflects the influence of mutagens. No significant difference was observed in the SCE frequency of metronidazole treated patient however, a statistically significant increase (P&lt;0.05) after nalidixic acid treatment could be described. We conclude that in spite of wide use of nalidixic acid for Trichomonas vaginalis infection, because of its potential genotoxic effect its usage must be individualized especially for pregnant women and small babies.</description><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/PL00007476</identifier><identifier>PMID: 10985613</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Acids ; Adult ; Animals ; Antitrichomonal Agents - therapeutic use ; Condoms ; Female ; Gene Frequency ; Genes - drug effects ; Humans ; Infections ; Metronidazole - therapeutic use ; Middle Aged ; Mutagenicity Tests ; Nalidixic Acid - therapeutic use ; Parasitic diseases ; Prospective Studies ; Sexually transmitted diseases ; Sister Chromatid Exchange ; STD ; Trichomonas vaginalis - genetics ; Trichomonas Vaginitis - drug therapy ; Trichomonas Vaginitis - parasitology</subject><ispartof>Archives of gynecology and obstetrics, 2000-07, Vol.264 (1), p.20-23</ispartof><rights>Archives of Gynecology and Obstetrics is a copyright of Springer, (2000). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-6f68922ce00570105108d99e299b2acadf08c26d42e39793207396cb331fbe253</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10985613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akyol, D</creatorcontrib><creatorcontrib>Mungan, T</creatorcontrib><creatorcontrib>Baltaci, V</creatorcontrib><title>A comparative study of genotoxic effects in the treatment of trichomonas vaginalis infection: metronidazole or nalidixic acid</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><description>We performed a prospective randomized study to compare the potential genotoxic effects of metronidazole and nalidixic acid which they are used in the treatment of Trichomonas vaginalis infection. 20 patients with Trichomonas vaginalis infections participated in this study. 14 patients with vaginal trichomoniasis were treated with therapeutic doses of metronidazole 250 mg 3 times/d and six patients were treated with nalidixic acid 400 mg twice a day for 10 d. The genotoxic potential of a variety of mutagenic and carcinogenic agents can be evaluated by sister-chromatid exchange (SCE) test as a rapid cytogenetic test. An increased number of exchanges in lymphocytes reflects the influence of mutagens. No significant difference was observed in the SCE frequency of metronidazole treated patient however, a statistically significant increase (P&lt;0.05) after nalidixic acid treatment could be described. We conclude that in spite of wide use of nalidixic acid for Trichomonas vaginalis infection, because of its potential genotoxic effect its usage must be individualized especially for pregnant women and small babies.</description><subject>Acids</subject><subject>Adult</subject><subject>Animals</subject><subject>Antitrichomonal Agents - therapeutic use</subject><subject>Condoms</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genes - drug effects</subject><subject>Humans</subject><subject>Infections</subject><subject>Metronidazole - therapeutic use</subject><subject>Middle Aged</subject><subject>Mutagenicity Tests</subject><subject>Nalidixic Acid - therapeutic use</subject><subject>Parasitic diseases</subject><subject>Prospective Studies</subject><subject>Sexually transmitted diseases</subject><subject>Sister Chromatid Exchange</subject><subject>STD</subject><subject>Trichomonas vaginalis - genetics</subject><subject>Trichomonas Vaginitis - drug therapy</subject><subject>Trichomonas Vaginitis - parasitology</subject><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpNkE1LAzEQhoMotlYv_gAJeBOqk6SbbLyV4hcU9KDnJZudbVO6m5qkxQr-d7u0oHOZOTzzMvMQcsnglgGou7cp7EqNlDwifTYSfAiKsWPSB93NIFWPnMW4AGA8z-Up6THQeSaZ6JOfMbW-WZlgktsgjWldbamv6Qxbn_yXsxTrGm2K1LU0zZGmgCY12KaOSsHZuW98ayLdmJlrzdJ1ZLfhfHtPG0zBt64y336J1AfaEZXrco111Tk5qc0y4sWhD8jH48P75Hk4fX16mYynQysYS0NZy1xzbhEgU8AgY5BXWiPXuuTGmqqG3HJZjTgKrXZPgxJa2lIIVpfIMzEg1_vcVfCfa4ypWPh12N0SC84lyzUI1VE3e8oGH2PAulgF15iwLRgUneniz_QOvjpErssGq3_oXq34BV_YeU8</recordid><startdate>20000701</startdate><enddate>20000701</enddate><creator>Akyol, D</creator><creator>Mungan, T</creator><creator>Baltaci, V</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20000701</creationdate><title>A comparative study of genotoxic effects in the treatment of trichomonas vaginalis infection: metronidazole or nalidixic acid</title><author>Akyol, D ; Mungan, T ; Baltaci, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-6f68922ce00570105108d99e299b2acadf08c26d42e39793207396cb331fbe253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acids</topic><topic>Adult</topic><topic>Animals</topic><topic>Antitrichomonal Agents - therapeutic use</topic><topic>Condoms</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genes - drug effects</topic><topic>Humans</topic><topic>Infections</topic><topic>Metronidazole - therapeutic use</topic><topic>Middle Aged</topic><topic>Mutagenicity Tests</topic><topic>Nalidixic Acid - therapeutic use</topic><topic>Parasitic diseases</topic><topic>Prospective Studies</topic><topic>Sexually transmitted diseases</topic><topic>Sister Chromatid Exchange</topic><topic>STD</topic><topic>Trichomonas vaginalis - genetics</topic><topic>Trichomonas Vaginitis - drug therapy</topic><topic>Trichomonas Vaginitis - parasitology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akyol, D</creatorcontrib><creatorcontrib>Mungan, T</creatorcontrib><creatorcontrib>Baltaci, V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akyol, D</au><au>Mungan, T</au><au>Baltaci, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparative study of genotoxic effects in the treatment of trichomonas vaginalis infection: metronidazole or nalidixic acid</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><addtitle>Arch Gynecol Obstet</addtitle><date>2000-07-01</date><risdate>2000</risdate><volume>264</volume><issue>1</issue><spage>20</spage><epage>23</epage><pages>20-23</pages><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>We performed a prospective randomized study to compare the potential genotoxic effects of metronidazole and nalidixic acid which they are used in the treatment of Trichomonas vaginalis infection. 20 patients with Trichomonas vaginalis infections participated in this study. 14 patients with vaginal trichomoniasis were treated with therapeutic doses of metronidazole 250 mg 3 times/d and six patients were treated with nalidixic acid 400 mg twice a day for 10 d. The genotoxic potential of a variety of mutagenic and carcinogenic agents can be evaluated by sister-chromatid exchange (SCE) test as a rapid cytogenetic test. An increased number of exchanges in lymphocytes reflects the influence of mutagens. No significant difference was observed in the SCE frequency of metronidazole treated patient however, a statistically significant increase (P&lt;0.05) after nalidixic acid treatment could be described. We conclude that in spite of wide use of nalidixic acid for Trichomonas vaginalis infection, because of its potential genotoxic effect its usage must be individualized especially for pregnant women and small babies.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>10985613</pmid><doi>10.1007/PL00007476</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0932-0067
ispartof Archives of gynecology and obstetrics, 2000-07, Vol.264 (1), p.20-23
issn 0932-0067
1432-0711
language eng
recordid cdi_proquest_journals_2261890375
source Springer Link
subjects Acids
Adult
Animals
Antitrichomonal Agents - therapeutic use
Condoms
Female
Gene Frequency
Genes - drug effects
Humans
Infections
Metronidazole - therapeutic use
Middle Aged
Mutagenicity Tests
Nalidixic Acid - therapeutic use
Parasitic diseases
Prospective Studies
Sexually transmitted diseases
Sister Chromatid Exchange
STD
Trichomonas vaginalis - genetics
Trichomonas Vaginitis - drug therapy
Trichomonas Vaginitis - parasitology
title A comparative study of genotoxic effects in the treatment of trichomonas vaginalis infection: metronidazole or nalidixic acid
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T06%3A23%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparative%20study%20of%20genotoxic%20effects%20in%20the%20treatment%20of%20trichomonas%20vaginalis%20infection:%20metronidazole%20or%20nalidixic%20acid&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Akyol,%20D&rft.date=2000-07-01&rft.volume=264&rft.issue=1&rft.spage=20&rft.epage=23&rft.pages=20-23&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/PL00007476&rft_dat=%3Cproquest_cross%3E2261890375%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-6f68922ce00570105108d99e299b2acadf08c26d42e39793207396cb331fbe253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2261890375&rft_id=info:pmid/10985613&rfr_iscdi=true